Complement-mediated immunotherapy to the Oral Squamous Cell Carcinoma with Cetuximab

西妥昔单抗补体介导的口腔鳞状细胞癌免疫治疗

• 批准号: 23792148
• 负责人: IMAI MASAKI
• 金额: $ 2.66万
• 依托单位: Nagoya City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23792148/
• 关键词: 口腔癌; 抗体; 免疫療法

To conserve both form and function in the oral area, effective and selective drugs against oral cancer will be required. We focused on Cetuximab, that is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing cancer. Complement deposition (C3) on HSC4 (human oral squamous cell carcinomas cell line) by incubation with Cetuximab and human serum was slightly enhanced. On the other hands, complement inhibitors expressed on tumor cells provide a hindrance to the therapeutic efficacy of some monoclonal antibodies. We investigated a strategy to amplify complement activation on tumor cells and overwhelm complement inhibitor function. Complement deposition and lysis of HSC4 cells by incubation with Cetuximab and human serum was enhanced in the presence of CR2-Fc. CR2-Fc enhances the therapeutic efficacy of antibody therapy and may provide particular benefits under conditions of limiting antibody concentration or low tumor antigen density.

为了保护口腔区域的形式和功能，需要有效和选择性的口腔癌药物。我们关注的是西妥昔单抗，它适用于治疗表皮生长因子受体（EGFR）表达的癌症患者。通过与西妥昔单抗和人血清孵育，HSC 4（人口腔鳞状细胞癌细胞系）上的补体沉积（C3）略有增强。另一方面，在肿瘤细胞上表达的补体抑制剂阻碍了一些单克隆抗体的治疗功效。我们研究了一种增强肿瘤细胞上补体激活并压倒补体抑制剂功能的策略。在存在CR2-Fc的情况下，通过与西妥昔单抗和人血清一起孵育的HSC 4细胞的补体沉积和裂解得到增强。CR2-Fc增强抗体疗法的治疗功效，并且可在限制抗体浓度或低肿瘤抗原密度的条件下提供特定益处。

项目成果

Novel complementary peptides to target molecules.

• 发表时间: 2011-07
• 期刊: Anticancer research
• 影响因子: 2
• 作者: H. Okada;M. Imai;F. Ono;Alan Okada;T. Tada;Y. Mizue;K. Terao;N. Okada

腫瘍の補体制御膜因子による免疫回避

肿瘤补体调节膜因子的免疫逃避

• 发表时间: 2011
• 期刊: 臨床免疫・アレルギー科
• 作者: Ohta R;Torii Y;Imai M;Kimura H;Okada N;Ito Y;Yukinori Takagi;高木幸則;今井優樹,岡田則子
• 通讯作者: 今井優樹,岡田則子

Interleukin-17A-Producing T Lymphocytes in Chronic Active Epstein-Barr Virus Infection.

慢性活动性 Epstein-Barr 病毒感染中产生白细胞介素 17A 的 T 淋巴细胞。

• DOI: 10.1111/1348-0421.12010
• 发表时间: 2013
• 期刊: Microbiology and Immunology
• 影响因子: 2.6
• 作者: Isobe Y;Hamano Y;Ito Y;Kimura H;Tsukada N;Sugimoto K;Komatsu N.;Ohta R
• 通讯作者: Ohta R

C5a is a target to prevent peritoneal tissue damage in acute peritoneal injury in rats

C5a是预防大鼠急性腹膜损伤中腹膜组织损伤的靶点

• 发表时间: 2012
• 作者: Mizuno T;Mizuno M;Imai M;Suzuki Y;Kushida M;Yamada K;Noda Y;Maruyama S;Okada H;Okada N;Matsuo S;Ito Y
• 通讯作者: Ito Y

口腔癌に対する抗MUC1モノクローナル抗体の抗腫瘍活性と補体膜制御因子の影響

抗MUC1单克隆抗体对口腔癌的抗肿瘤活性及补体膜调节因子的影响

• 发表时间: 2012
• 作者: 今井優樹,太田里永子;岡田則子
• 通讯作者: 岡田則子